Souillet G, Guffon N, Maire I, Pujol M, Taylor P, Sevin F, Bleyzac N, Mulier C, Durin A, Kebaili K, Galambrun C, Bertrand Y, Froissart R, Dorche C, Gebuhrer L, Garin C, Berard J, Guibaud P
Department of Paediatric Immuno-Hematology and Bone Marrow Transplantation, Debrousse Hospital, Lyon, France.
Bone Marrow Transplant. 2003 Jun;31(12):1105-17. doi: 10.1038/sj.bmt.1704105.
Over the last 15 years, we have performed a total of 30 haematopoietic stem cell transplants on 27 children suffering from Hurler's syndrome. These children were of median age 11 months at the time of diagnosis and 25 months at the time of transplantation. The phenotype was severe in 21 cases (78%). The donor was familial in 13 cases: nine genotypically identical, one phenotypically identical father and three HLA-mismatched donors. Unrelated donors were selected in 17 cases: four phenotypically identical and 13 with 1-4 HLA mismatches. The conditioning regimen generally consisted of busulphan 600 mg/m(2) plus cyclophosphamide (Endoxan) 260 mg/kg and cyclosporin with methotrexate for GvHD prophylaxis. Rabbit anti-thymocyte globulin (Thymoglobuline) was given for all unrelated or familial mismatched transplantations. The median nucleated cell dose infused was 6.00 x 10(8) TNC/kg. No bone marrow (apart from one) was T cell depleted. For first transplants, engraftment was observed in 23/27 patients (pts) (85%). Primary graft failure was observed in 4/27 patients (16%), two were retransplanted from an unrelated donor, one with success. Four patients have died. The primary cause of death was infection in three cases (TRM : 11%) and disease progression in one case, after primary graft failure. Of the 23 living patients, two have disease progression after graft failure and 21 (78%) have functional grafts with a favourable long-term outcome after a median follow-up of 4.7 years, having either full or mixed chimaerism. Among surviving patients with functional grafts, 13 (62%) were transplanted from unrelated donors of whom 10 (77 %) had HLA disparities. There was a remarkably low incidence of GvHD. In our experience, haematopoietic stem cell transplantation using an HLA-matched familial donor or an HLA-matched or -mismatched unrelated donor without T cell depletion or irradiation can achieve a favourable outcome in Hurler's syndrome, with improved cognitive function, but with a limited effect on the corneas and skeleton.
在过去15年里,我们共对27例患有Hurler综合征的儿童进行了30次造血干细胞移植。这些儿童诊断时的中位年龄为11个月,移植时为25个月。21例(78%)患儿的表型严重。13例供者为家庭成员:9例基因完全相同,1例表型相同的父亲,3例HLA不匹配的供者。17例选择了非亲属供者:4例表型相同,13例有1 - 4个HLA位点不匹配。预处理方案一般包括白消安600 mg/m²加环磷酰胺(癌得星)260 mg/kg以及用于预防移植物抗宿主病(GvHD)的环孢素和甲氨蝶呤。所有非亲属或亲属不匹配的移植均给予兔抗胸腺细胞球蛋白(即复宁)。输注的有核细胞剂量中位数为6.00×10⁸个有核细胞/kg。除1例之外,所有骨髓均未进行T细胞去除。首次移植时,23/27例患者(85%)观察到植入。4/27例患者(16%)出现原发性移植失败,其中2例接受了来自非亲属供者的再次移植,1例成功。4例患者死亡。主要死亡原因3例为感染(移植相关死亡率:11%),1例在原发性移植失败后因疾病进展死亡。在23例存活患者中,2例在移植失败后出现疾病进展,21例(78%)有功能正常的移植物,中位随访4.7年后长期预后良好,呈现完全或混合嵌合体状态。在存活的有功能移植物的患者中,13例(62%)接受了非亲属供者的移植,其中10例(77%)存在HLA差异。移植物抗宿主病的发生率极低。根据我们的经验,使用HLA匹配的亲属供者或HLA匹配或不匹配的非亲属供者进行造血干细胞移植,不进行T细胞去除或照射,在Hurler综合征中可取得良好的预后,认知功能得到改善,但对角膜和骨骼的影响有限。